Longboard Pharmaceuticals Announced Monday It Would Host Call To Discuss Topline Data From PACIFIC Study, a Phase 1b/2a Clinical Trial For Bexicaserin In Participants With Developmental And Epileptic Encephalopathies Tuesday At 8:30 AM ET
Portfolio Pulse from Charles Gross
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is set to host a conference call to discuss the topline data from the PACIFIC Study, a Phase 1b/2a clinical trial for bexicaserin in participants with Developmental and Epileptic Encephalopathies (DEEs). The call is scheduled for January 2, at 8:30 AM ET. Bexicaserin is a novel 5-HT2C receptor superagonist with potential therapeutic benefits and no observed impact on other receptor subtypes.
January 02, 2024 | 10:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longboard Pharmaceuticals will share important clinical trial results for bexicaserin, which could significantly impact the company's stock depending on the outcomes.
The announcement of topline data from a clinical trial is a critical event for a biopharmaceutical company, especially one in the clinical stage like LBPH. Positive results could lead to a surge in stock price due to increased investor confidence in the drug's potential. Conversely, negative results could have the opposite effect. Given that this is a Phase 1b/2a trial, the results will give significant insights into the drug's efficacy and safety, which are crucial for its continued development and potential commercialization.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100